Lipid-lowering: Can ezetimibe help close the treatment gap?

Ryan C. Neal; Peter H. Jones

doi:10.3949/ccjm.70.9.777

Lipid-lowering: Can ezetimibe help close the treatment gap?

Ryan C. Neal, Peter H. Jones

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Most patients who should be on lipid-lowering therapy are not receiving it, and most patients who are receiving it are not reaching their appropriate low-density lipoprotein (LDL) goals. This is in part because physicians and patients fear side effects of statins and other lipid-lowering agents. Ezetimibe (Zetia), a new lipid-lowering drug, may help physicians close this "treatment gap" in more patients, especially in combination with a statin.

Original language	English (US)
Pages (from-to)	777-783
Number of pages	7
Journal	Cleveland Clinic journal of medicine
Volume	70
Issue number	9
DOIs	https://doi.org/10.3949/ccjm.70.9.777
State	Published - Sep 1 2003

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.3949/ccjm.70.9.777

Cite this

@article{d0cc034411fc473996e52b72d93a70da,

title = "Lipid-lowering: Can ezetimibe help close the treatment gap?",

abstract = "Most patients who should be on lipid-lowering therapy are not receiving it, and most patients who are receiving it are not reaching their appropriate low-density lipoprotein (LDL) goals. This is in part because physicians and patients fear side effects of statins and other lipid-lowering agents. Ezetimibe (Zetia), a new lipid-lowering drug, may help physicians close this {"}treatment gap{"} in more patients, especially in combination with a statin.",

author = "Neal, {Ryan C.} and Jones, {Peter H.}",

year = "2003",

month = sep,

day = "1",

doi = "10.3949/ccjm.70.9.777",

language = "English (US)",

volume = "70",

pages = "777--783",

journal = "Cleveland Clinic journal of medicine",

issn = "0891-1150",

publisher = "Cleveland Clinic Educational Foundation",

number = "9",

}

TY - JOUR

T1 - Lipid-lowering

T2 - Can ezetimibe help close the treatment gap?

AU - Neal, Ryan C.

AU - Jones, Peter H.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Most patients who should be on lipid-lowering therapy are not receiving it, and most patients who are receiving it are not reaching their appropriate low-density lipoprotein (LDL) goals. This is in part because physicians and patients fear side effects of statins and other lipid-lowering agents. Ezetimibe (Zetia), a new lipid-lowering drug, may help physicians close this "treatment gap" in more patients, especially in combination with a statin.

AB - Most patients who should be on lipid-lowering therapy are not receiving it, and most patients who are receiving it are not reaching their appropriate low-density lipoprotein (LDL) goals. This is in part because physicians and patients fear side effects of statins and other lipid-lowering agents. Ezetimibe (Zetia), a new lipid-lowering drug, may help physicians close this "treatment gap" in more patients, especially in combination with a statin.

UR - http://www.scopus.com/inward/record.url?scp=0141787011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141787011&partnerID=8YFLogxK

U2 - 10.3949/ccjm.70.9.777

DO - 10.3949/ccjm.70.9.777

M3 - Review article

C2 - 14518572

AN - SCOPUS:0141787011

SN - 0891-1150

VL - 70

SP - 777

EP - 783

JO - Cleveland Clinic journal of medicine

JF - Cleveland Clinic journal of medicine

IS - 9

ER -

Lipid-lowering: Can ezetimibe help close the treatment gap?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this